Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-26, Stock:ABBV, The news for the past five days is as follows:
2019-12-18: NEWS1: AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL).NEWS2: AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis.NEWS3: AbbVie’s Humira Sales in Europe Appear to Be Holding Up Better Than Anticipated.NEWS4: ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway.
2019-12-19: NEWS1: AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU.
2019-12-20: NEWS1: Key AbbVie Drug Faces Competition Worries After Head-to-Head Study.NEWS2: Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs.NEWS3: AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes.NEWS4: Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?.
2019-12-23: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: Top Stock Reports for SAP, AbbVie & Sinopec.
2019-12-24: NEWS1: The Zacks Analyst Blog Highlights: SAP, AbbVie, Sinopec, Cigna and Intuitive Surgical.NEWS2: Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - December 24, 2019.NEWS3: ImmunoGen Lead Drug Gets Nod for Accelerated Approval Pathway (Revised).NEWS4: Here’s to Your Health: A Decade of Drug Breakthroughs.

Answer: Decrease